Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis

doi:10.3748/wjg.v29.i34.5075

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4319)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2427

Figures (1-1)

269

Tables (1-3)

302

Sum=3116

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

158

Download

395

Sum=553

Publishing Process of This Article

Item

Count

Browse

155

Download

335

Sum=490

Sep 14, 2023 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 14, 2023; 29(34): 5075-5081
Published online Sep 14, 2023. doi: 10.3748/wjg.v29.i34.5075

Table 1 Clinical and laboratory data of patients with primary biliary cholangitis

	Early-stage (stages I + II; n = 48)	Stage III (n = 22)	Stage IV (n = 12)	P value
ALT	53.5 (29.5-124.5)	54.0 (30.0-127.6)	80.0 (42.8-127.4)	0.639
AST	53.5 (34.0-97.3)^a	68.5 (39.6-114.1)	112.2 (81.1-136.3)	0.009
TBA	9.0 (3.6-36.4)^a	18.0 (7.0-45.1)	28.2 (18.0-111.5)	0.011
TBIL	15.4 (11.2-27.8)^a	16.7 (13.7-24.2)^a	61.2 (28.1-114.3)	0.002
DBIL	5.2 (3.7-16.0)^a	8.7 (2.5-12.4)^a	42.3 (15.8-67.3)	0.003
ALB	42.1 (38.3-44.8)^a	39.3 (36.5-42.5)	35.8 (30. 5-41.0)	0.005
A/G	1.2 (1.1-1.4)^a	1.0 (0.9-1.3)	0.9 (0.7-1.1)	0.001
ALP	200.4 (117.8-414.0)^a	292.5 (162.0-421.3)	463.5 (329.6-770.5)	0.008
GGT	289.0 (133.0-668.8)	532.0 (326. 5-764.3)	336.5 (264.0-648.0)	0.070
CHO	5.8 (4.6-6.9)	6.2 (5.1-7.5)	6.8 (4.9-7.0)	0.509
TG	1.3 (1.0-1.8)	1.6 (1.2-2.1)^a	1.1 (0.8-1.5)	0.019
IgG	16.7 ± 4.6	17.6 ± 6.7	20.6 ± 7.9	0.056
IgA	2.9 (2.1-3.3)	3.5 (2.5-4.7)	3.4 (2.4-4.4)	0.031
IgM	3.4 (1.8-5.1)	3.7 (2.1-5.0)	3.7 (1.9-6.8)	0.967
C3	1.4 (1.2-1.6)	1.6 (1.3-1.8)	1.2 (1.0-1.7)	0.126
C4	0.2 (0.2-0.3)	0.2 (0.2-0.3)	0.2 (0.2-0.3)	0.963

^aP < 0.05 indicates statistically significant difference compared to stage IV.

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBA: Total bile acid; ALP: Alkaline phosphatase; GGT: γ-glutamyl transferase; ALB: Albumin; A/G: Albumin/globulin; TBIL: Total bilirubin, DBIL: Direct bilirubin; CHO: Cholesterol; TG: Triglycerides; IgG: Immunoglobulin G; IgM: Immunoglobulin M; IgA: Immunoglobulin A; C3: Complement 3; C4: Complement 4.

Table 2 Autoantibody positive rate in patients with early-stage primary biliary cholangitis

Autoantibody	AMA	AMA-M2	Anti-sp100	Anti-gp210	Anti-SSA/Ro52	Anti-SSA/Ro60	ANA
n	32	22	8	9	8	2	34
%	66.7	45.8	16.7	18.8	16.7	4.2	70.8

AMA: Anti-mitochondria antibody; ANA: Anti-nuclear antibody.

Table 3 Anti-nuclear antibody subtype positive rate in patients with early-stage primary biliary cholangitis

ANA	Cytoplasmic speckled	Fibrillar	Reticular	Discrete	Homogeneous	Centromere	Nuclear speckled	Nucleolar	Nuclear
n	24	2	6	7	1	6	5	0	10
%	50	4.2	12.5	14.6	2.1	12.5	10.4	0	20.8

ANA: Anti-nuclear antibody.

Citation: Zhu YJ, Li J, Liu YG, Jiang Y, Cheng XJ, Han X, Wang CY, Li J. Role of biochemical markers and autoantibodies in diagnosis of early-stage primary biliary cholangitis. World J Gastroenterol 2023; 29(34): 5075-5081
URL: https://www.wjgnet.com/1007-9327/full/v29/i34/5075.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i34.5075